Cardiovascular

Ischaemic Stroke

Reviewed September 8, 2026 7 views

The largest meta-analysis of stroke genetics found that the loci belong to subtypes rather than to stroke. A clot from the heart and a blocked neck artery are different diseases that end in the same emergency.

What this condition connects to

Ischaemic Stroke Variant: rs13407662 rs13407662 Variant Variant: rs2107595 rs2107595 Variant Variant: rs879324 rs879324 Variant Ischaemic Stroke Ischaemic Stroke Cardiovascul…
Prevalence
One of the leading causes of death and of acquired disability worldwide, and the great majority of strokes are ischaemic rather than haemorrhagic. Incidence rises steeply with age.
Inheritance
Polygenic, and the loci belong to subtypes rather than to ischaemic stroke as a whole — cardioembolic risk tracks atrial fibrillation genetics, large-vessel risk tracks atherosclerosis genetics. Rare monogenic causes such as CADASIL exist and are separate entities.

An ischaemic stroke is a blocked blood vessel in the brain. Tissue downstream begins to die within minutes, which is why the whole of stroke medicine is organised around time.

But "blocked" covers several different events. A clot can form in the heart — usually in atrial fibrillation — and travel up. A large artery in the neck or at the base of the brain can narrow with atherosclerosis and occlude. A tiny deep vessel can close off on its own. Same emergency, three different diseases.

What happens when you stop treating them as one thing

The METASTROKE collaboration meta-analysed 15 cohorts: 12,389 people with ischaemic stroke and 62,004 controls, all of European ancestry, with replication of new signals in 13,347 cases and 29,083 controls.

The associations it verified were subtype-specific:

Read that again in terms of what it means. The genetics of cardioembolic stroke is the genetics of an irregular heartbeat. The genetics of large-vessel stroke is the genetics of arteries furring up. Neither is the genetics of "stroke".

Why that is a useful finding rather than a technicality

It says the subtype classification clinicians use is not merely descriptive — it separates conditions with different causes. That supports treating them differently, which is already what happens: anticoagulation for a heart in atrial fibrillation, and a different approach for a furred-up carotid.

It also explains why studies that pooled all ischaemic strokes found so little for so long. Three signals were being averaged into noise.

What three positions do not do

They do not predict a stroke. The dominant risks are ones you can name without a genome: blood pressure, atrial fibrillation, smoking, diabetes, cholesterol, age. Blood pressure alone outweighs everything on this page.

And in the moment none of it matters. Stroke treatment runs on imaging and on the clock — face drooping, arm weakness, speech difficulty, time to call emergency services. If that is happening now, stop reading.

Clinical detail

Source. The METASTROKE collaboration (Lancet Neurol 2012) meta-analysed data from 15 ischaemic stroke cohorts totalling 12,389 cases and 62,004 controls, all of European ancestry, with conditional analysis on the lead SNP in each associated region and replication of novel suggestive signals in 13,347 cases and 29,083 controls. Previously reported associations were verified for cardioembolic stroke near PITX2 (p = 2.8 × 10⁻¹⁶) and at ZFHX3 (p = 2.28 × 10⁻⁸), and for large-vessel stroke at a 9p21 locus (p = 3.32 × 10⁻⁵) and HDAC9 (p = 2.03 × 10⁻¹²).

Positions listed here. rs2107595 at HDAC9 (large-vessel), rs879324 at ZFHX3 (cardioembolic), and rs13407662 at ASB3, recorded by the collector from the same study.

Subtype specificity. The verified associations attach to TOAST-classified subtypes rather than to ischaemic stroke as a whole. PITX2 and ZFHX3 are established atrial fibrillation loci and their appearance under cardioembolic stroke is consistent with mechanism rather than independent of it; 9p21 is shared with coronary artery disease. Pooled all-stroke analyses dilute subtype-specific signals, which is the practical reason earlier all-cause analyses were unrewarding.

Clinical use. None. Acute management is determined by imaging and time from onset — thrombolysis and mechanical thrombectomy within defined windows. Secondary prevention is directed by the identified mechanism, in particular anticoagulation for atrial fibrillation, and by conventional risk factor management. No genotype is used to select acute or preventive therapy.

Population. All cohorts were of European ancestry. Stroke subtype distribution itself differs between populations, so both effect sizes and the relative importance of each subtype should be expected to differ elsewhere.

Related variants MyGeneLog checks for

What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Ischaemic Stroke comes down to these specific, well-studied positions — not a diagnosis.

Sensitive

Stroke (ischemic)

ASB3 · rs13407662

See detailed info →
Sensitive

Stroke (ischemic)

HDAC9 · rs2107595

See detailed info →
Sensitive

Stroke (ischemic)

ZFHX3 · rs879324

See detailed info →

Sources

Frequently asked questions

Why do the genes differ between stroke subtypes?

Because the subtypes are different diseases that end in the same emergency. A clot thrown from a fibrillating heart and a neck artery narrowed by atherosclerosis arrive at the same place by different routes, and the genetics follows the route: PITX2 and ZFHX3 are atrial fibrillation genes, 9p21 is a coronary artery disease locus.

Can these variants predict my stroke risk?

No, and the things that do predict it are already known and mostly modifiable: blood pressure, atrial fibrillation, smoking, diabetes, cholesterol, age. Blood pressure alone outweighs everything on this page.

Why did earlier stroke studies find so little?

Largely because they pooled the subtypes. Averaging three different diseases together dilutes each one’s signal, and separating them is what made these associations visible.

Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.